FindTrial
Sign In

Phase II Trial of Neoadjuvant ALIMTA plus Cisplatin followed by Surgery and Radiation in the Treatment of Pleural Mesothelioma

Phase II Trial of Neoadjuvant ALIMTA plus Cisplatin followed by Surgery and Radiation in the Treatment of Pleural Mesothelioma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002537-39-IT
Enrollment
Unknown
Registered
2005-02-02
Start date
2005-04-04
Completion date
Unknown
Last updated
2012-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaural Mesothelioma MedDRA version: 14.1 Level: PT Classification code 10059518 Term: Pleural mesothelioma malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: Alimta Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: pemetrexed CAS Number: 150399-23-8 Current Sponsor code: MTA, LY231514 Concentration unit: mg milligram(s)

Sponsors

ELI LILLY
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026